Markston International LLC decreased its position in MetLife, Inc. (NYSE:MET) by 10.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 146,126 shares of the company’s stock after selling 17,575 shares during the period. Markston International LLC’s holdings in MetLife were worth $6,492,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in MET. Premier Fund Managers Ltd boosted its position in shares of MetLife by 19.1% in the second quarter. Premier Fund Managers Ltd now owns 66,700 shares of the company’s stock worth $2,614,000 after buying an additional 10,700 shares in the last quarter. Northpointe Capital LLC acquired a new position in shares of MetLife during the second quarter worth approximately $3,861,000. Deprince Race & Zollo Inc. boosted its position in shares of MetLife by 6.7% in the second quarter. Deprince Race & Zollo Inc. now owns 722,124 shares of the company’s stock worth $28,762,000 after buying an additional 45,507 shares in the last quarter. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new position in shares of MetLife during the second quarter worth approximately $110,000. Finally, First New York Securities LLC NY acquired a new position in shares of MetLife during the second quarter worth approximately $119,000. Hedge funds and other institutional investors own 75.21% of the company’s stock.
MetLife, Inc. (NYSE:MET) traded up 1.88% during mid-day trading on Wednesday, reaching $55.94. 1,222,678 shares of the company’s stock were exchanged. The firm has a market cap of $61.49 billion, a price-to-earnings ratio of 17.19 and a beta of 1.69. The stock has a 50-day moving average of $54.80 and a 200-day moving average of $47.89. MetLife, Inc. has a 12 month low of $35.00 and a 12 month high of $58.09.
MetLife (NYSE:MET) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $1.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.04. MetLife had a net margin of 5.58% and a return on equity of 6.99%. The company earned $17.70 billion during the quarter, compared to the consensus estimate of $17.03 billion. During the same quarter in the prior year, the firm posted $0.62 EPS. The firm’s quarterly revenue was down 99.9% on a year-over-year basis. Analysts anticipate that MetLife, Inc. will post $4.65 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, March 13th. Stockholders of record on Monday, February 6th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date of this dividend is Thursday, February 2nd. MetLife’s dividend payout ratio (DPR) is presently 49.23%.
Several research firms have recently weighed in on MET. Standpoint Research lowered shares of MetLife from a “buy” rating to a “hold” rating in a report on Friday, December 9th. FBR & Co lowered shares of MetLife from an “outperform” rating to a “market perform” rating and set a $54.00 price objective for the company. in a report on Monday, November 28th. They noted that the move was a valuation call. Deutsche Bank AG raised shares of MetLife from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a report on Monday. Zacks Investment Research lowered shares of MetLife from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. Finally, Argus reaffirmed a “buy” rating and set a $54.00 price objective on shares of MetLife in a report on Tuesday, November 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. MetLife currently has a consensus rating of “Buy” and a consensus target price of $53.31.
In other news, EVP Frans Hijkoop sold 56,250 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $51.48, for a total transaction of $2,895,750.00. Following the completion of the sale, the executive vice president now owns 111,813 shares of the company’s stock, valued at approximately $5,756,133.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Peter M. Carlson sold 23,636 shares of the company’s stock in a transaction that occurred on Friday, December 23rd. The stock was sold at an average price of $54.32, for a total transaction of $1,283,907.52. Following the sale, the executive vice president now directly owns 39,914 shares of the company’s stock, valued at approximately $2,168,128.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 97,083 shares of company stock valued at $5,126,315. 0.27% of the stock is currently owned by insiders.
MetLife, Inc (MetLife) is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America (collectively, the Americas); Asia, and Europe, the Middle East and Africa (EMEA).
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET).